Rafferty Asset Management LLC Makes New $1.74 Million Investment in Capricor Therapeutics Inc (NASDAQ:CAPR)

Rafferty Asset Management LLC acquired a new position in shares of Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 126,311 shares of the biotechnology company's stock, valued at approximately $1,743,000. Rafferty Asset Management LLC owned about 0.28% of Capricor Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. increased its position in Capricor Therapeutics by 419.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 56,199 shares of the biotechnology company's stock worth $855,000 after buying an additional 45,381 shares during the period. Magnus Financial Group LLC acquired a new stake in shares of Capricor Therapeutics in the fourth quarter worth $276,000. SG Americas Securities LLC increased its position in Capricor Therapeutics by 74.8% during the fourth quarter. SG Americas Securities LLC now owns 15,317 shares of the biotechnology company's stock worth $211,000 after acquiring an additional 6,552 shares during the period. Rhumbline Advisers raised its stake in Capricor Therapeutics by 44.4% during the 4th quarter. Rhumbline Advisers now owns 46,083 shares of the biotechnology company's stock valued at $636,000 after purchasing an additional 14,169 shares during the last quarter. Finally, New York State Common Retirement Fund raised its stake in Capricor Therapeutics by 625.0% during the 4th quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company's stock valued at $80,000 after purchasing an additional 5,000 shares during the last quarter. Institutional investors own 21.68% of the company's stock.

Capricor Therapeutics Stock Performance

Shares of NASDAQ:CAPR traded down $0.61 during midday trading on Monday, reaching $10.25. 1,665,784 shares of the company's stock were exchanged, compared to its average volume of 1,734,938. The company's 50 day simple moving average is $10.50 and its two-hundred day simple moving average is $13.39. Capricor Therapeutics Inc has a 12 month low of $3.52 and a 12 month high of $23.40. The firm has a market capitalization of $468.19 million, a PE ratio of -9.67 and a beta of 0.85.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The biotechnology company reported ($0.53) EPS for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.20). The business had revenue of $2.73 million for the quarter, compared to the consensus estimate of $3.16 million. Capricor Therapeutics had a negative return on equity of 112.95% and a negative net margin of 146.86%. During the same quarter in the prior year, the business earned ($0.31) EPS. On average, research analysts anticipate that Capricor Therapeutics Inc will post -1.21 earnings per share for the current year.

Wall Street Analyst Weigh In

CAPR has been the topic of several research analyst reports. HC Wainwright restated a "buy" rating and issued a $77.00 price target on shares of Capricor Therapeutics in a research report on Monday, March 17th. Roth Capital initiated coverage on shares of Capricor Therapeutics in a research note on Tuesday, May 20th. They issued a "buy" rating and a $31.00 target price for the company. Wall Street Zen lowered Capricor Therapeutics from a "hold" rating to a "sell" rating in a research note on Thursday. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $30.00 price target on shares of Capricor Therapeutics in a report on Wednesday, May 14th. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company's stock. According to MarketBeat, Capricor Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $35.50.

Capricor Therapeutics Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.